Certolizumab pegol - Axial spondyloarthritis

You are here : Home > Formulary Search > Certolizumab pegol - Axial spondyloarthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Subcutaneous injection (sc)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines BNF SPC

ICB

NICE

Restrictions / Comments :

Documentation

NICE Technology Appraisal

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non radiographic axial spondyloarth

PAD Profile

ChemicalSubstance :

Certolizumab pegol

Indication :

Axial spondyloarthritis

Group Name :

Keywords :

Biologic, anti-TNF, TNF-alpha, monoclonal antibody, cytokine modulator, nrAS, nr-AS, non-radiographic axial spondyloarthritis, ankylosing spondylitis

Brand Names Include :

Cimzia

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Axial spondyloarthritis

Supporting Documents :

Other Indications

Below are listed other indications that Certolizumab pegol is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Axial spondyloarthritis.

Committee Recommendations (2)

05 Feb 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated axial spondyloarthritis pathway.

Treatment pathway is available on separate guidelines page.

06 Jul 16 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN agreed the attached Spondyloarthritis biologic treatment pathway in line with TA383 which was published by NICE in February 2016